Publications

• Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer.

  (Tsai S, George B, Wittmann D, Ritch PS, Krepline AN, Aldakkak M, Barnes CA, Christians KK, Dua K, Griffin M, Hagen C, Hall WA, Erickson BA, Evans DB.) Ann Surg. 2020 Apr;271(4):740-747 PMID: 30312198 SCOPUS ID: 2-s2.0-85082099572 10/13/2018

• Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation.

  (Norkin M, Shaw BE, Brazauskas R, Tecca HR, Leather HL, Gea-Banacloche J, T Kamble R, DeFilipp Z, Jacobsohn DA, Ringden O, Inamoto Y, A Kasow K, Buchbinder D, Shaw P, Hematti P, Schears R, Badawy SM, Lazarus HM, Bhatt N, Horn B, Chhabra S, M Page K, Hamilton B, Hildebrandt GC, Yared JA, Agrawal V, M Beitinjaneh A, Majhail N, Kindwall-Keller T, Olsson RF, Schoemans H, Gale RP, Ganguly S, A Ahmed I, Schouten HC, L Liesveld J, Khera N, Steinberg A, Shah AJ, Solh M, Marks DI, Rybka W, Aljurf M, Dietz AC, Gergis U, George B, Seo S, Flowers MED, Battiwalla M, Savani BN, Riches ML, Wingard JR.) Biol Blood Marrow Transplant. 2019 02;25(2):362-368 PMID: 30287390 PMCID: PMC6339825 SCOPUS ID: 2-s2.0-85055972080 10/06/2018

• A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma.

  (Tsai S, Christians KK, George B, Ritch PS, Dua K, Khan A, Mackinnon AC, Tolat P, Ahmad SA, Hall WA, Erickson BA, Evans DB.) Ann Surg. 2018 10;268(4):610-619 PMID: 30080723 SCOPUS ID: 2-s2.0-85067054610 08/07/2018

• Locally advanced pancreas cancer: Staging and goals of therapy.

  (Chatzizacharias NA, Tsai S, Griffin M, Tolat P, Ritch P, George B, Barnes C, Aldakkak M, Khan AH, Hall W, Erickson B, Evans DB, Christians KK.) Surgery. 2018 05;163(5):1053-1062 PMID: 29331400 SCOPUS ID: 2-s2.0-85040254084 01/15/2018

• Should functional renal scans be obtained prior to upper abdominal IMRT for pancreatic cancer?

  (Blitzer GC, Hall WA, Tsai S, Aldakkak M, Hellman RS, Evans DB, Christians KK, George B, Ritch PS, Erickson BA.) Pract Radiat Oncol. 2017 Nov - Dec;7(6):e449-e455 PMID: 28886941 SCOPUS ID: 2-s2.0-85028763165 09/10/2017

• Comprehensive Analysis of Hypermutation in Human Cancer.

  (Campbell BB, Light N, Fabrizio D, Zatzman M, Fuligni F, de Borja R, Davidson S, Edwards M, Elvin JA, Hodel KP, Zahurancik WJ, Suo Z, Lipman T, Wimmer K, Kratz CP, Bowers DC, Laetsch TW, Dunn GP, Johanns TM, Grimmer MR, Smirnov IV, Larouche V, Samuel D, Bronsema A, Osborn M, Stearns D, Raman P, Cole KA, Storm PB, Yalon M, Opocher E, Mason G, Thomas GA, Sabel M, George B, Ziegler DS, Lindhorst S, Issai VM, Constantini S, Toledano H, Elhasid R, Farah R, Dvir R, Dirks P, Huang A, Galati MA, Chung J, Ramaswamy V, Irwin MS, Aronson M, Durno C, Taylor MD, Rechavi G, Maris JM, Bouffet E, Hawkins C, Costello JF, Meyn MS, Pursell ZF, Malkin D, Tabori U, Shlien A.) Cell. 2017 Nov 16;171(5):1042-1056.e10 PMID: 29056344 PMCID: PMC5849393 10/24/2017

• Is Adjuvant Therapy Necessary for All Patients with Localized Pancreatic Cancer Who Have Received Neoadjuvant Therapy?

  (Barnes CA, Krepline AN, Aldakkak M, Clarke CN, Christians KK, Khan AH, Hunt BC, Ritch PS, George B, Hall WA, Erickson BA, Evans DB, Tsai S.) J Gastrointest Surg. 2017 Nov;21(11):1793-1803 PMID: 28849366 SCOPUS ID: 2-s2.0-85028529403 08/30/2017

• Poor Glycemic Control Is Associated with Failure to Complete Neoadjuvant Therapy and Surgery in Patients with Localized Pancreatic Cancer.

  (Rajamanickam ES, Christians KK, Aldakkak M, Krepline AN, Ritch PS, George B, Erickson BA, Foley WD, Aburajab M, Evans DB, Tsai S.) J Gastrointest Surg. 2017 03;21(3):496-505 PMID: 27896658 SCOPUS ID: 2-s2.0-84997795492 11/30/2016

• Multimodality Therapy in Patients With Borderline Resectable or Locally Advanced Pancreatic Cancer: Importance of Locoregional Therapies for a Systemic Disease.

  (Tsai S, Christians KK, Ritch PS, George B, Khan AH, Erickson B, Evans DB.) J Oncol Pract. 2016 10;12(10):915-923 PMID: 27858562 SCOPUS ID: 2-s2.0-84991252464 11/20/2016

• Venous thromboembolism prophylaxis during neoadjuvant therapy for resectable and borderline resectable pancreatic cancer-Is it indicated?

  (Krepline AN, Christians KK, George B, Ritch PS, Erickson BA, Tolat P, Evans DB, Tsai S.) J Surg Oncol. 2016 Oct;114(5):581-586 PMID: 27760280 SCOPUS ID: 2-s2.0-84992111849 10/22/2016

• High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients.

  (Conte B, George B, Overman M, Estrella J, Jiang ZQ, Mehrvarz Sarshekeh A, Ferrarotto R, Hoff PM, Rashid A, Yao JC, Kopetz S, Dasari A.) Clin Colorectal Cancer. 2016 Jun;15(2):e1-7 PMID: 26810202 PMCID: PMC4885752 01/27/2016

• Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy.

  (Christians KK, Heimler JW, George B, Ritch PS, Erickson BA, Johnston F, Tolat PP, Foley WD, Evans DB, Tsai S.) Surgery. 2016 Mar;159(3):893-900 PMID: 26602840 SCOPUS ID: 2-s2.0-84950987094 11/26/2015